Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tschoepe, D.
Right arrow Articles by Gries, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tschoepe, D.
Right arrow Articles by Gries, F. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 44, Issue 8 890-894, Copyright © 1995 by American Diabetes Association

ARTICLES

Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia

D Tschoepe, E Driesch, B Schwippert, HK Nieuwenhuis and FA Gries
Diabetes Research Institute, Heinrich Heine University, Duesseldorf, Germany.

It has been suggested that platelet hyperactivity contributes to the early evolution of diabetic vascular disease per se. This study directly evaluates the level of intravascular platelet activation in newly diagnosed IDDM patients before and after tight metabolic control. Platelet activation was determined by the Duesseldorf-III flow cytometry assay in 21 recent-onset hyperglycemic IDDM patients before insulin, after 3 days of treatment with intravenous insulin, and after 14 and 60 days of intensified conventional insulin therapy. The intravasal platelet activation status was quantified by the percentage of platelets exposing the activation-dependent molecules CD62 (P-selectin), thrombospondin (TSP), and CD63 (GP53) as well as the activated fibrinogen receptor (GPIIB/IIIA). Fifty matched normal subjects served as control subjects. Fourteen patients completed the 60-day study design. After initial recompensation, near-normoglycemic control was achieved after 14 days (fasting blood glucose, 117.0 +/- 19.0 mg/dl), and the HbA1 concentration was 7.6 +/- 1.2% after 60 days. CD62+ (4.0 +/- 4.5%), TSP+ (2.0 +/- 1.8%), CD63+ (11.0 +/- 7.0%), and activated-GPIIB/IIIA+ (7.6 +/- 7.7%) platelet levels were initially 5, 3.3, 5.7, and 2.8 times higher than the mean level of normal. There was no correlation with any of the nearly normalized metabolic parameters. Thus, more activated platelets circulate in newly diagnosed IDDM patients, which supports the assumption of a prethrombotic condition even in disease stages without apparent vascular damage.(ABSTRACT TRUNCATED AT 250 WORDS)
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CLIN APPL THROMB HEMOSTHome page
N. Bavbek, A. Kargili, O. Kaftan, F. Karakurt, A. Kosar, and A. Akcay
Elevated Concentrations of Soluble Adhesion Molecules and Large Platelets in Diabetic Patients: Are They Markers of Vascular Disease and Diabetic Nephropathy?
Clinical and Applied Thrombosis/Hemostasis, October 1, 2007; 13(4): 391 - 397.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
E. I. Lev, R. T. Patel, K. J. Maresh, S. Guthikonda, J. Granada, T. DeLao, P. F. Bray, and N. S. Kleiman
Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention: The Role of Dual Drug Resistance
J. Am. Coll. Cardiol., January 3, 2006; 47(1): 27 - 33.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. I. Lev, R. T. Patel, K. J. Maresh, S. Guthikonda, J. Granada, T. DeLao, P. F. Bray, and N. S. Kleiman
Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention: The Role of Dual Drug Resistance
J. Am. Coll. Cardiol., December 13, 2005; (2005) j.jacc.2005.08.058v1.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. Fiorina, F. Folli, A. D'Angelo, G. Finzi, F. Pellegatta, V. Guzzi, C. Fedeli, P. D. Valle, L. Usellini, C. Placidi, et al.
Normalization of Multiple Hemostatic Abnormalities in Uremic Type 1 Diabetic Patients After Kidney-Pancreas Transplantation
Diabetes, September 1, 2004; 53(9): 2291 - 2300.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
H. Koyama, T. Maeno, S. Fukumoto, T. Shoji, T. Yamane, H. Yokoyama, M. Emoto, T. Shoji, H. Tahara, M. Inaba, et al.
Platelet P-Selectin Expression Is Associated With Atherosclerotic Wall Thickness in Carotid Artery in Humans
Circulation, August 5, 2003; 108(5): 524 - 529.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. Sabatier, P. Darmon, B. Hugel, V. Combes, M. Sanmarco, J.-G. Velut, D. Arnoux, P. Charpiot, J.-M. Freyssinet, C. Oliver, et al.
Type 1 And Type 2 Diabetic Patients Display Different Patterns of Cellular Microparticles
Diabetes, September 1, 2002; 51(9): 2840 - 2845.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
A. Shouzu, S. Nomura, T. Hayakawa, S. Omoto, H. Shimizu, Y. Miyake, T. Yonemoto, S. Fukuhara, T. Iwasaka, M. Nishikawa, et al.
State-of-the-Art Review : Effect of Sarpogrelate Hydrochloride on Platelet-Derived Microparticles and Various Soluble Adhesion Molecules in Diabetes Mellitus
Clinical and Applied Thrombosis/Hemostasis, July 1, 2000; 6(3): 139 - 143.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1995 by the American Diabetes Association.